Added sugar, derived from cheap crops like corn, is bad for babies. According to the American Heart Association, added sugars ...

Mitolyn is a natural weight loss supplement made with plant ingredients with proper clinical backing. The formula is ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

In looking at the profound impact on satiety that GLP-1s have, Penn State College of Medicine Drs. Patrician Grigson and ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amgen Inc.

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

Scholar Rock is developing apitegromab, an anti-latent myostatin antibody in late-stage development for spinal muscular atrophy, as a potential obesity treatment ... the U.S. FDA has noted ...

After several trials, the FDA approved the first GLP-1 medication for weight loss in 2021, branded as Wegovy. Dr. Shweta Akhouri is a board-certified family and obesity medicine physician.

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicines.